January 11, 2026 04:22 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
IPAC raid row escalates! ED drags Mamata Banerjee to Supreme Court after High Court chaos | 'Easy way or hard way': Trump doubles down on controversial push to acquire Greenland | Hindu tenant farmer shot dead in Pakistan’s Sindh, sparks massive protests | India vs NYC Mayor: MEA hits back after Mamdani backs jailed activist Umar Khalid | US Commerce Secretary blames India for trade deal failure: 'Modi didn’t call Trump' | Jana Nayagan controversy: Madras HC steps in, orders CBFC to clear Vijay film | Telecom shakeup: Vodafone Idea shares soar as AGR dues finally sorted | Dragged by police outside Amit Shah’s office! 8 TMC MPs detained as ED row explodes | Trump backs bill threatening 500% tariffs on India over Russian oil trade | ED alleges Mamata 'forcibly removed documents' during IPAC raids, CM calls Amit Shah 'nasty Home Minister'
Johnson&Johnson Vaccine

Kolkata's Peerless Hospital commences Johnson & Johnson vaccine's clinical trial

| @indiablooms | May 08, 2021, at 03:50 am

Kolkata/IBNS: Kolkata's Peerless Hospital has been selected as the only trial venue in the East for Johnson & Johnson for their single-dose vaccine which is currently being used under emergency authorization.

In a statement Dr Subhrajyoti Bhowmick, Clinical trial specialist and clinical Pharmacologist and Director, Clinical Research Peerless Hospital, Kolkata said, " We shall be recruiting 100 participants at this site, six such sites have been selected for this trial of this unique single dose vaccine."

"I am confident we shall get enough volunteers for the clinical trial as vaccine supply is short and the supply of Covishield and Covaxine is less than the huge demand. The ratio shall be 3:1 as three volunteers will get a vaccine while one person shall get a placebo. We are now awaiting the ethics committee approval on which we shall embark on the clinical trials," concluded Bhowmick.

Earlier, Sputnik V, developed by Gamaleya Research Institute of Epidemiology and Microbiology in Russia, has been approved for use in India.

Five million doses of Sputnik V are expected to arrive in India by June.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.